CoChat

Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance

Ishengoma, Deus S, Mandara, Celine I, Bakari, Catherine, Fola, Abebe A, Madebe, Rashid A, Seth, Misago D, Francis, Filbert, Buguzi, Creyton C, Moshi, Ramadhan, Garimo, Issa, Lazaro, Samwel, Lusasi, Abdallah, Aaron, Sijenunu, Chacky, Frank, Mohamed, Ally, Njau, Ritha J A, Kitau, Jovin, Rasmussen, Charlotte, Bailey, Jeffrey A, Juliano, Jonathan J, Warsame, Marian · 2024 · The Lancet Infectious Diseases
Cited by 131

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1473-3099(24)00362-1

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 23

  1. Dimbu, 2021, Continued low efficacy of artemether–lumefantrine in Angola in 2019, Antimicrob Agents Chemother, 65, e01949, 10.1128/AAC.01949-20 · doi:10.1128/aac.01949-20
  2. Gansané, 2021, Anti-malarial efficacy and resistance monitoring of artemether–lumefantrine and dihydroartemisinin–piperaquine shows inadequate efficacy in children in Burkina Faso, 2017–2018, Malar J, 20, 48, 10.1186/s12936-021-03585-6 · DOI
  3. Moriarty, 2021, Therapeutic efficacy of artemisinin-based combination therapies in Democratic Republic of the Congo and investigation of molecular markers of antimalarial resistance, Am J Trop Med Hyg, 105, 1067, 10.4269/ajtmh.21-0214 · DOI
  4. Ebong, 2021, Efficacy and safety of artemether–lumefantrine and dihydroartemisinin–piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria and prevalence of molecular markers associated with artemisinin and partner drug resistance in Uganda, Malar J, 20, 484, 10.1186/s12936-021-04021-5 · DOI
  5. Rasmussen, 2021, Is there evidence of anti-malarial multidrug resistance in Burkina Faso?, Malar J, 20, 320, 10.1186/s12936-021-03845-5 · doi:10.1186/s12936-021-03845-5
  6. Uwimana, 2021, Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study, Lancet Infect Dis, 21, 1120, 10.1016/S1473-3099(21)00142-0 · DOI · Paper page
  7. Balikagala, 2021, Evidence of artemisinin-resistant malaria in Africa, N Engl J Med, 385, 1163, 10.1056/NEJMoa2101746 · DOI · Paper page
  8. Mihreteab, 2023, Increasing prevalence of artemisinin-resistant HRP2-negative malaria in Eritrea, N Engl J Med, 389, 1191, 10.1056/NEJMoa2210956 · DOI · Paper page
  9. Mandara, 2018, High efficacy of artemether–lumefantrine and dihydroartemisinin–piperaquine for the treatment of uncomplicated falciparum malaria in Muheza and Kigoma districts, Tanzania, Malar J, 17, 261, 10.1186/s12936-018-2409-z · DOI
  10. Ishengoma, 2019, Efficacy and safety of artemether–lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania, Malar J, 18, 88, 10.1186/s12936-019-2730-1 · DOI
  11. Juliano, 2023, Country wide surveillance reveals prevalent artemisinin partial resistance mutations with evidence for multiple origins and expansion of high level sulfadoxine–pyrimethamine resistance mutations in northwest Tanzania, medRxiv
  12. Ariey, 2014, A molecular marker of artemisinin-resistant Plasmodium falciparum malaria, Nature, 505, 50, 10.1038/nature12876 · DOI · Paper page
  13. Oyola, 2016, Whole genome sequencing of Plasmodium falciparum from dried blood spots using selective whole genome amplification, Malar J, 15, 597, 10.1186/s12936-016-1641-7 · doi:10.1186/s12936-016-1641-7
  14. Uwimana, 2020, Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda, Nat Med, 26, 1602, 10.1038/s41591-020-1005-2 · DOI · Paper page
  15. Abdel Hamid, 2023, Pf7: an open dataset of Plasmodium falciparum genome variation in 20,000 worldwide samples, Wellcome Open Res, 8, 22, 10.12688/wellcomeopenres.18681.1 · DOI · Paper page
  16. Flegg, 2011, Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator, Malar J, 10, 339, 10.1186/1475-2875-10-339 · DOI · Paper page
  17. Ataide, 2017, Host immunity to Plasmodium falciparum and the assessment of emerging artemisinin resistance in a multinational cohort, Proc Natl Acad Sci USA, 114, 3515, 10.1073/pnas.1615875114 · DOI
  18. Imwong, 2017, Spread of a single multidrug resistant malaria parasite lineage (PfPailin) to Vietnam, Lancet Infect Dis, 17, 1022, 10.1016/S1473-3099(17)30524-8 · DOI · Paper page
  19. Jeang, 2024, Molecular surveillance of kelch13 polymorphisms in Plasmodium falciparum isolates from Kenya and Ethiopia, Malar J, 23, 36, 10.1186/s12936-023-04812-y · DOI
  20. Adam, 2023, Antimalarial drug efficacy and resistance in malaria-endemic countries in HANMAT-PIAM_net countries of the Eastern Mediterranean region 2016–2020: clinical and genetic studies, Trop Med Int Health, 28, 817, 10.1111/tmi.13929 · DOI
  21. Schreidah, 2024, Expansion of artemisinin partial resistance mutations and lack of histidine rich protein-2 and -3 deletions in Plasmodium falciparum infections from Rukara, Rwanda, Malar J, 23, 150, 10.1186/s12936-024-04981-4 · DOI
  22. van Loon, 2024, Escalating marker prevalence indicative of artemisinin resistance in southern Rwanda, Antimicrob Agents Chemother, 68, 10.1128/aac.01299-23 · DOI
  23. Rosenthal, 2024, Emergence, transmission dynamics and mechanisms of artemisinin partial resistance in malaria parasites in Africa, Nat Rev Microbiol, 22, 373, 10.1038/s41579-024-01008-2 · DOI · Paper page

Cited by

See all 131

Metadata

Authors
Ishengoma, D. S., Mandara, C. I., Bakari, C., Fola, A. A., Madebe, R. A., Seth, M. D., Francis, F., Buguzi, C. C., Moshi, R., Garimo, I., Lazaro, S., Lusasi, A., Aaron, S., Chacky, F., Mohamed, A., Njau, R. J. A., Kitau, J., Rasmussen, C., Bailey, J. A., Juliano, J. J., & Warsame, M.
Venue
The Lancet Infectious Diseases
Publisher
Elsevier BV
Published
2024-11
Volume
24
Issue
11
Pages
1225-1233
ISSN
1473-3099
Cited by
131
References
3
Language
en
Licence
Funders
  • National Institute for Medical Research
  • Bill and Melinda Gates Foundation (002202, OPP1209843)
  • National Institutes of Health (R01AI156267, K24AI134990)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance. https://app.cochat.ai/papers/10.1016/s1473-3099(24)00362-1
The paper
Ishengoma, D. S., Mandara, C. I., Bakari, C., Fola, A. A., Madebe, R. A., Seth, M. D., Francis, F., Buguzi, C. C., Moshi, R., Garimo, I., Lazaro, S., Lusasi, A., Aaron, S., Chacky, F., Mohamed, A., Njau, R. J. A., Kitau, J., Rasmussen, C., Bailey, J. A., . . . Warsame, M. (2024). Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(24)00362-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.